Cargando…
Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer
Breast cancer is the second leading cause of cancer death among women. Human epidermal receptor 2 (HER2) positive breast cancer (HER2+ BC) is the most aggressive subtype of breast cancer, with poor prognosis and a high rate of recurrence. About one third of breast cancer is HER2+ BC with significant...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187895/ https://www.ncbi.nlm.nih.gov/pubmed/27983617 http://dx.doi.org/10.3390/ijms17122095 |
_version_ | 1782486922109648896 |
---|---|
author | Lv, Quanxia Meng, Ziyuan Yu, Yuanyuan Jiang, Feng Guan, Daogang Liang, Chao Zhou, Junwei Lu, Aiping Zhang, Ge |
author_facet | Lv, Quanxia Meng, Ziyuan Yu, Yuanyuan Jiang, Feng Guan, Daogang Liang, Chao Zhou, Junwei Lu, Aiping Zhang, Ge |
author_sort | Lv, Quanxia |
collection | PubMed |
description | Breast cancer is the second leading cause of cancer death among women. Human epidermal receptor 2 (HER2) positive breast cancer (HER2+ BC) is the most aggressive subtype of breast cancer, with poor prognosis and a high rate of recurrence. About one third of breast cancer is HER2+ BC with significantly high expression level of HER2 protein compared to other subtypes. Therefore, HER2 is an important biomarker and an ideal target for developing therapeutic strategies for the treatment HER2+ BC. In this review, HER2 structure and physiological and pathological roles in HER2+ BC are discussed. Two diagnostic tests, immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH), for evaluating HER2 expression levels are briefly introduced. The current mainstay targeted therapies for HER2+ BC include monoclonal antibodies, small molecule tyrosine kinase inhibitors, antibody–drug conjugates (ADC) and other emerging anti-HER2 agents. In clinical practice, combination therapies are commonly adopted in order to achieve synergistic drug response. This review will help to better understand the molecular mechanism of HER2+ BC and further facilitate the development of more effective therapeutic strategies against HER2+ BC. |
format | Online Article Text |
id | pubmed-5187895 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-51878952016-12-30 Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer Lv, Quanxia Meng, Ziyuan Yu, Yuanyuan Jiang, Feng Guan, Daogang Liang, Chao Zhou, Junwei Lu, Aiping Zhang, Ge Int J Mol Sci Review Breast cancer is the second leading cause of cancer death among women. Human epidermal receptor 2 (HER2) positive breast cancer (HER2+ BC) is the most aggressive subtype of breast cancer, with poor prognosis and a high rate of recurrence. About one third of breast cancer is HER2+ BC with significantly high expression level of HER2 protein compared to other subtypes. Therefore, HER2 is an important biomarker and an ideal target for developing therapeutic strategies for the treatment HER2+ BC. In this review, HER2 structure and physiological and pathological roles in HER2+ BC are discussed. Two diagnostic tests, immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH), for evaluating HER2 expression levels are briefly introduced. The current mainstay targeted therapies for HER2+ BC include monoclonal antibodies, small molecule tyrosine kinase inhibitors, antibody–drug conjugates (ADC) and other emerging anti-HER2 agents. In clinical practice, combination therapies are commonly adopted in order to achieve synergistic drug response. This review will help to better understand the molecular mechanism of HER2+ BC and further facilitate the development of more effective therapeutic strategies against HER2+ BC. MDPI 2016-12-14 /pmc/articles/PMC5187895/ /pubmed/27983617 http://dx.doi.org/10.3390/ijms17122095 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Lv, Quanxia Meng, Ziyuan Yu, Yuanyuan Jiang, Feng Guan, Daogang Liang, Chao Zhou, Junwei Lu, Aiping Zhang, Ge Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer |
title | Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer |
title_full | Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer |
title_fullStr | Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer |
title_full_unstemmed | Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer |
title_short | Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer |
title_sort | molecular mechanisms and translational therapies for human epidermal receptor 2 positive breast cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187895/ https://www.ncbi.nlm.nih.gov/pubmed/27983617 http://dx.doi.org/10.3390/ijms17122095 |
work_keys_str_mv | AT lvquanxia molecularmechanismsandtranslationaltherapiesforhumanepidermalreceptor2positivebreastcancer AT mengziyuan molecularmechanismsandtranslationaltherapiesforhumanepidermalreceptor2positivebreastcancer AT yuyuanyuan molecularmechanismsandtranslationaltherapiesforhumanepidermalreceptor2positivebreastcancer AT jiangfeng molecularmechanismsandtranslationaltherapiesforhumanepidermalreceptor2positivebreastcancer AT guandaogang molecularmechanismsandtranslationaltherapiesforhumanepidermalreceptor2positivebreastcancer AT liangchao molecularmechanismsandtranslationaltherapiesforhumanepidermalreceptor2positivebreastcancer AT zhoujunwei molecularmechanismsandtranslationaltherapiesforhumanepidermalreceptor2positivebreastcancer AT luaiping molecularmechanismsandtranslationaltherapiesforhumanepidermalreceptor2positivebreastcancer AT zhangge molecularmechanismsandtranslationaltherapiesforhumanepidermalreceptor2positivebreastcancer |